Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.RNAC · Entity 6015 | Director | December 16, 2025 | December 18, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date December 16, 2025 · Filed December 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,800 |
Reported balance
After 2025-12-16 transaction · row 1
1 source rowRow 1 · 2025-12-16 · Grant · Acquired 5,800 · Balance 5,800 F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments following the date of grant so that the underlying shares will be fully vested on December 16, 2028. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.29 · Expires 2035-12-15 | Direct | 17,200 |
Reported balance
After 2025-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-16 · Grant · Acquired 17,200 · Balance 17,200 F2: This award will vest in 36 equal monthly installments, so that it shall be fully vested on December 16, 2028. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments following the date of grant so that the underlying shares will be fully vested on December 16, 2028.
F2: This award will vest in 36 equal monthly installments, so that it shall be fully vested on December 16, 2028.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2025 Filed Dec 18, 2025 22:05 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 17,200 | $0.00 Strike: $8.29 | $0.00 |
DisclosureSEC source: 0001453687-25-000144 · wk-form4_1766095515.xml · derivative · entry 2 Bot Adrian Ion · CIK 0002101801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,200 Underlying: Common Stock · 17,200 shares Expires 2035-12-15 F2 · derivative.exercise_date: This award will vest in 36 equal monthly installments, so that it shall be fully vested on December 16, 2028. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:05 UTC | Cartesian Therapeutics, Inc. RNAC · Entity 6015 | GrantCommon Stock | 5,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001453687-25-000144 · wk-form4_1766095515.xml · nonDerivative · entry 1 Bot Adrian Ion · CIK 0002101801 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,800 F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest in three equal annual installments following the date of grant so that the underlying shares will be fully vested on December 16, 2028. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.